ACE and lung adenocarcinoma: A significant association between ACE inhibition and NSCLC (OR, 0.922; 95% CI, 0.816–1.028; p = 0.132) was not observed, including lung adenocarcinoma (OR, 1.008; 95% CI, 0.830–1.186; p = 0.929) and lung squamous cell carcinoma (OR, 0.917; 95% CI, 0.697–1.137; p = 0.440) (Supplementary Table S6).